Cell therapy with tolerogenic antigen-presenting cells (tolAPC) shows promise for treating autoimmune diseases and preventing transplant rejection.

Phase 1 trials completed:

- Type 1 diabetes
- Rheumatoid arthritis
- Crohn's disease



We developed MITAP (Minimum Information about Tolerogenic Antigen-Presenting cells).



MITAP is a reporting framework with checklists that allow the scientific community to better use and interpret tolAPC data.

- Facilitate experimental reproducibility
- Enable data sharing + highlight differences between tolAPC products
- Streamline creation of standardised tolAPC for clinical appliations

1. Cells Before

Characteristics and state of cells before tolAPC manipulation



2. Differentiation & Induction of Tolerogenicity

Describes pre-culture and culture conditions, and differentiation + induction of tolerogenic functions





4. About the Protocol

General features of the protocol as a whole, as well as purpose of the produced toIAPC.



3. Cells After

Characteristics and state of cells after tolAPC manipulation. Includes details such as phenotype, number of cells, and viability.



MITAP is a first but important step towards producing **standardised** and **reproducible tolAPC**.

